|Articles|April 1, 2016
Number of Countries in Phase III Studies Remains Steady
Author(s)Harold E. Glass, PhD
Trend doesn't seem to fall in line with the perception of an increasingly complex trial protocol climate.
Advertisement
Are pharmaceutical company Phase III clinical trials becoming more complex? The most broadly based database available, ClinicalTrials.gov, does not support the assertion that clinical trials have become more complex in study/protocol design or execution. Illustrative is the number of countries used in pharmaceutical company sponsored Phase III clinical studies.
The number of countries used in commercially sponsored Phase III trials has not changed in recent years. It is essential to stratify the results or otherwise the data appear to show that the number of countries per study has actually declined. The chart at right stratifies the studies by planned study duration: less than one year, 1 to 2 years and 3 or more years. This is important because the longer the planned study, the more likely the study may be opening sites in additional countries. When stratified this way, the data show practically no change over the years covered.
Articles in this issue
over 9 years ago
EMA Releases New Advice on Human Trials for Cancer Drugsover 9 years ago
Number of Countries in Phase III Studies Remains Steadyover 9 years ago
Will EMA Rules Calm the Disclosure Debate?over 9 years ago
Acknowledging Cycle Time Impact from Protocol Amendmentsover 9 years ago
The Promise of Precision Medicineover 9 years ago
Value-Based Planning & Drug Development Productivityover 9 years ago
Overcoming Early Phase Oncology Challengesover 9 years ago
Imagining the Impossible: Immunity to Cancerover 9 years ago
Applied Clinical Trials, April/May 2016 Issue (PDF)Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Using AI Trial-Matching Tools to Accelerate Patient Access
September 8th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Beyond the Algorithm: How Human-Centered AI Design Can Drive Clinical Trial Success
2
ACT Brief Episode 7: Veeva and Merck Trial Efficiency, DCT Barriers, and Glucose Monitoring Strategies
3
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
4
Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer
5